EPANED KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EPANED KIT (EPANED KIT).
Vitamin B12 (cobalamin) is a cofactor for methionine synthase and methylmalonyl-CoA mutase, essential for DNA synthesis, myelin formation, and hematopoiesis. It also reduces homocysteine levels.
| Metabolism | Hydroxocobalamin is converted to methylcobalamin and adenosylcobalamin in the liver. It undergoes enterohepatic recycling and is primarily excreted unchanged in bile, with minimal renal excretion. |
| Excretion | Renal: 50-70% as unchanged drug; biliary/fecal: 20-30% as metabolites; minimal respiratory excretion. |
| Half-life | Terminal elimination half-life: 2.4–3.2 hours in healthy adults; prolonged to 5–10 hours in hepatic impairment; clinically relevant for dosing interval adjustment. |
| Protein binding | 90–95% primarily to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.3–0.5 L/kg; indicates distribution mainly into extracellular fluid and well-perfused tissues. |
| Bioavailability | Intravenous: 100%; intramuscular: 75–85%; oral: 40–60% (first-pass effect). |
| Onset of Action | Intravenous: 5–10 minutes; intramuscular: 15–30 minutes; oral: 30–60 minutes. |
| Duration of Action | Intravenous: 2–4 hours; intramuscular: 3–6 hours; oral: 4–8 hours; duration may be extended in hepatic dysfunction. |
Intravenous: 0.5-1 mg/kg/dose (max 50 mg/dose) every 6 hours as needed for nausea and vomiting.
| Dosage form | FOR SOLUTION |
| Renal impairment | GFR 10-50 mL/min: No adjustment. GFR <10 mL/min: Not recommended due to propylene glycol accumulation. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B or C: Maximum 150 mg/day (total daily dose) due to reduced clearance. |
| Pediatric use | Children 2-12 years: 0.5-1 mg/kg/dose (max 25 mg/dose) IV every 6 hours. Infants <2 years: 0.5 mg/kg/dose IV every 6 hours. Not recommended for neonates. |
| Geriatric use | No specific dose adjustment, but consider reduced clearance; use lowest effective dose and monitor for anticholinergic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EPANED KIT (EPANED KIT).
| Breastfeeding | Minimal excretion into breast milk is expected. The M/P ratio is not established. Use with caution; hydroxyprogesterone caproate may decrease milk production. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for the drug. |
| Teratogenic Risk | EPANED KIT (hydroxyprogesterone caproate) is a progestin. First trimester: No evidence of increased risk of major birth defects based on clinical studies and postmarketing surveillance, but animal studies with high doses showed some developmental effects. Second and third trimesters: No teratogenic effects; used to reduce risk of preterm birth. Long-term follow-up of exposed children shows no increased rate of congenital anomalies. |
■ FDA Black Box Warning
No black box warning.
| Serious Effects |
["Hypersensitivity to hydroxocobalamin, cyanocobalamin, or cobalt","Leber's disease (hereditary optic nerve atrophy)"]
| Precautions | ["May cause hypokalemia and increased platelet count during initial treatment of pernicious anemia; monitor potassium levels.","Avoid in patients with cobalt hypersensitivity (cobalt is a component of hydroxocobalamin).","Not suitable for leber's disease (hereditary optic nerve atrophy) due to risk of optic atrophy.","May interact with nitrous oxide (inactivates cobalamin) and chloramphenicol (antagonizes hematologic response)."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, fluid balance, and signs of thromboembolic events. Fetal monitoring includes serial ultrasound for growth, amniotic fluid index, and fetal heart rate. Assess for signs of gestational diabetes. No specific laboratory monitoring required beyond routine prenatal care. |
| Fertility Effects | No known significant effects on fertility. As a progestin, it may inhibit ovulation at high doses, but the low dose in pregnancy use is not intended for contraception. Return to fertility after discontinuation is expected. |